菲格拉斯汀
医学
生物仿制药
聚乙二醇非格司亭
中性粒细胞减少症
粒细胞集落刺激因子
发热性中性粒细胞减少症
化疗
肿瘤科
重症监护医学
内科学
癌症
作者
Jason Xu,Steven Jonathan,Xu Jessica,Xing Zhao,Qiang Yan
出处
期刊:Annals of bone marrow research
[Peertechz Publications Private Limited]
日期:2023-09-12
卷期号:8 (1): 001-004
摘要
Chemotherapy-Induced Neutropenia (CIN) is a potentially fatal side effect of cancer treatment, affecting > 50% of cancer patients treated with chemotherapy. Clinical use of recombinant human granulocyte colony-stimulating factor (rhG-CSF) has allowed for primary and secondary prophylaxis of CIN and its sequela (i.e., febrile neutropenia, fatal infection) during myelosuppressive chemotherapy. Here, we review the translation and properties of first, second, and third-generation rhG-CSF molecules, including filgrastim (Neupogen, FDA approved in 1991) and biosimilars, pegfilgrastim (Neulasta, FDA approved in 2002) and biosimilars, and F-627 (Ryzneuta, NMPA approved in 2023), a novel long-acting rhG-CSF agent developed this past decade. Even with the development of increasingly personalized and targeted cancer therapy, chemotherapy, and stem cell transplantation remains a backbone for the majority of patients with advanced cancers, especially in the hematopoietic system. As such, more than 20 million cancer patients have been treated with rhG-CSF drugs since the first approval of filgrastim. In the next decade, we envision third-generation rhG-CSF products such as Ryzneuta lowering costs to patients and healthcare providers, expanding access to this essential medication for cancer patients worldwide, particularly for patients who require more aggressive chemotherapy treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI